GSK punts $2.2 billion on global collaboration in immuno-neurology

3 July 2021
gsk-building-big

Under pressure from activist  Elliott to up its performance, UK pharma major GlaxoSmithKline (LSE: GSK) on Friday revealed it has entered into a strategic global collaboration with USA-based biotech firm Alector (Nasdaq: ALEC) to develop potential new drugs for Parkinson’s and Alzheimer’s disease.

Alector’s shares rocketed more than 57% to $34.21 by close of trading yesterday, having hit a high of $43.32 in early activity. After a small early lift, GSK’s stock closed virtually unchanged.

The deal is for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology